Context: Glycemic disturbance is usually less severe in pregnant women with type 2 than in those with type 1 diabetes mellitus (DM). Nevertheless, a worse perinatal outcome in women with type 2 DM has been reported in some studies.
Our aim has been to perform a systematic review and metaanalysis on maternal and fetal outcomes in pregnant women with type 2 vs. type 1 DM to quantify the risk of adverse outcomes in these pregnancies.
Subjects and Methods
We performed a systematic Medline search for studies on pregnancy outcome in women with established diabetes before pregnancy with no language restriction. We used the following search terms: diabetes mellitus AND pregnancy AND (pregestational OR type 1 diabetes mellitus OR type 2 diabetes mellitus OR insulindependent OR non insulindependent). Search was limited to human studies and a publication period ranging from January 1, 1987 , to June 30, 2008 . The search was last updated on July 27, 2008 . Two independent investigators considered all titles and abstracts for eligibility, and discrepancies were solved with a third one. Whenever an abstract suggested that the article could fulfill the entry criteria, the corresponding full text was assessed. References and review articles were checked looking for additional relevant studies.
Inclusion and exclusion criteria
We included studies that fulfilled all the following entry criteria: 1) provided original data of pregnancies in women with type 1 and type 2 DM, 2) an arbitrary minimum number of 15 pregnancies for each type of DM, and 3) gave information on at least one outcome of interest. We excluded studies if 1) the population was biased (i.e. women with type 2 DM were limited to those requiring insulin treatment) or 2) there was data overlap in different studies of the same center; in this case, the study reporting the biggest series was used.
Outcomes of interest
We defined four main outcomes [major congenital malformations (MCM), stillbirth (SB), neonatal mortality (NM), and perinatal mortality (PNM)] and 15 secondary ones (diabetic ketoacidosis, hypoglycemic coma, pregnancy-induced hypertension including preeclampsia, preeclampsia, cesarean section, miscarriage, termination, preterm birth, macrosomia, large for gestational age newborns, small for gestational age newborns, minor congenital malformations, hypoglycemia, respiratory distress, and jaundice).
Data collection
We extracted relevant data in predesigned forms on country of study, year of publication, number of pregnancies, maternal background characteristics (ethnicity, age, body mass index (BMI), DM duration, chronic hypertension, retinopathy, nephropathy, prepregnancy care, and gestational age at booking), metabolic control [glycated hemoglobin (HbA1c) expressed in percentage at booking and second and third trimesters), and outcomes of interest.
Ethical review board approval
Ethical review board approval was not required.
Statistics
Background characteristics were summarized, weighting by SE. Formal statistical comparison was not performed because results would be expressed as odds ratio (OR), and weighted means were considered to be better for descriptive purposes. For maternal and fetal outcomes, metaanalyses were conducted using Review Manager Software (version 4.2.10). We pooled outcomes from original studies calculating the OR of an event occurring, and significance for overall effect was assessed with a Z test. Because we expected some statistical heterogeneity within included studies, we employed a random-effects model to pool the data, setting statistical significance at a P value Ͻ0.05. To describe the percentage of total variation across studies attributable to heterogeneity, we used the statistic I 2 (7). Whenever OR was close to significance and I 2 was low (7), an additional analysis was performed using a fixed-effects model.
Post hoc analyses using metaregression tools (Stata version 10.0, restricted maximum likelihood method) were performed to evaluate the influence on primary outcomes of other potentially predictive variables (BMI, age, diabetes duration, and HbA1c).
Quality control
Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed (8) . Quality assessment of individual studies was performed using a scale specific for cohort studies, which uses a star rating system to judge quality based on three aspects of the study: selection of groups, comparability, and ascertainment of the outcomes of interest. The validity of this tool has been previously established (9) .
Maternal characteristics and outcomes of interest were not always defined. The first analysis of both main and secondary outcomes included all papers fulfilling entry criteria considering that the same criteria were applied to both types of DM. To test whether results would differ with the inclusion of papers not providing a definition or using a different one, a second analysis was performed for main outcomes including only papers providing similar outcome definition.
Funnel plot asymmetry was assessed with graphical and statistical methods (Egger's test) (10).
Results
Literature search and studies included (Fig. 1) The search strategy retrieved 3743 abstracts, and 153 full-text articles were examined. Of them, 33 were included (Table 1 and supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org); these studies fulfilled the inclusion criteria but not exclusion ones. Countries of origin of included papers were from Europe, Africa, United States, Japan, Australia, and New Zealand with a total of 3781 pregnancies in women with type 2 and 7966 in women with type 1 DM. We defined data overlap as exclusion criterion. Nevertheless, several special situations arose.
In centers participating in the Confidential Enquiry into Maternal and Child Health (CEMACH) (5) or French Diabetic Pregnancy Group studies (13, 25) and at the same time publishing single-center data (4, 16, 27, 29) , there was a minor overlap in the collaborative and single-center studies. Both collaborative and single-center studies were included.
Some authors reported different outcomes in different papers but with significant overlap in the study groups (Refs. 22 and 29 and Refs. 24 and 34). Patient characteristics and pregnancy outcomes reported in both papers have been taken for the study describing the largest population (29, 34) ; outcomes reported in only one of the papers were retrieved from this specific one (i.e. PNM from Ref. 22 or MCM from Ref. 24) .
Some studies reported outcome data on women with type 2 DM separating known and newly presenting categories (24, 34) . In these cases, only data of women with known type 2 DM have been included. A slightly different situation arose with the article of Sacks et al. (18) , which under the heading of type 2 DM reported combined data of women with pregestational type 2 DM (n ϭ 78) and women diagnosed in the first trimester of pregnancy (n ϭ 35; fasting blood glucose Ն140 mg/dl). We retained this paper because the diagnosis in the first trimester and the especially severe condition (median fasting blood glucose 160 mg/dl) made the assumption of pregestational DM highly likely.
None of the articles selected according to inclusion/ exclusion criteria was rejected as a result of quality as- sessment. All studies qualified well in the outcome scale. The comparability of the cohorts was not assessable because papers did not specify referral criteria for women with type 1 and type 2 DM. As to the selection scale, groups differed not only in the type of DM but also in associated characteristics (i.e. age and BMI); however, this was not considered to invalidate the comparison because these characteristics are intrinsic to the type of DM.
Background maternal characteristics
In comparison with women with type 1 DM, those with type 2 were older and heavier, had higher rates of chronic hypertension and lower rates of prepregnancy care, and booked later for antenatal care; they had shorter DM duration, a lower rate of diabetic complications, and lower HbA1c at booking and throughout pregnancy (Table 2) .
Main outcomes (Figs. 2 and 3)
Heterogeneity (I 2 ) was low or moderate for all outcomes. Compared with women with type 1 DM, those with type 2 had a higher risk of PNM [OR 1.50, confidence interval (CI) 1.15-1.96] with similar OR for MCM, SB, and NM. Additional analyses using fixed-effects model or including only papers where definition of primary outcomes was provided, yielded similar OR (data not shown).
Meta-regression analyses on the four primary outcomes did not identify any significant predictor. It is important to highlight that the number of studies included for univariate analyses ranged from 28.6 -100% of the original ones, whereas all multivariate analyses included less than 30% of the papers.
Secondary outcomes (Table 3)
Heterogeneity (I 2 ) was low or moderate for all but one (hypoglycemic coma) of the 15 secondary outcomes. In women with type 2 DM, a significant lower risk of diabetic ketoacidosis and cesarean section was observed, with a trend toward a lower risk of hypoglycemic coma. The visual inspection of funnel plots for MCM, SB, PNM, NN (supplemental Fig. 1) , and all secondary outcomes (data not shown) displayed a symmetrical distribution, and Egger's test was not significant for bias.
Discussion
This systematic review and metaanalysis of 33 observational studies published in the last 20 yr has shown that pregnant women with type 2 DM have a higher risk of PNM than women with type 1 DM with no differences in the rates of MCM, SB, and NM. As to the 10 secondary outcomes, women with type 2 DM displayed a lower risk of diabetic ketoacidosis and cesarean section.
The strength of this study is to be the first attempt to summarize pregnancy outcomes in women with type 2 vs. type 1 DM, covering studies published worldwide during more than 20 yr. Different ethnicities were represented, although a higher proportion corresponded to Caucasian women. We found it difficult to deal with overlap in papers originating from the same center, and we chose to retain as much information as possible whenever overlap was considered to be minor. Another drawback was that some papers did not provide the definition for reported outcomes; however, because the subanalyses including only those providing definitions yielded similar results, we have used the results of the entire study group. Background maternal characteristics (age, BMI, DM duration, chronic hypertension, microangiopathic complications, and glycemic control) are concordant with the features of the type of DM and disease duration. As to the lower rate of prepregnancy care and higher gestational age at booking in women with type 2 DM, they could be attributed to higher rates of deprivation (4) and less frequent care by an endocrinologist in these women, a feature that has been associated with seeking prepregnancy care (40) .
Even when women with type 2 DM attended less often for prepregnancy care and booked later for antenatal care, they had better HbA1c not only at booking but also throughout pregnancy. This could be attributed to better ␤-cell function due to intrinsic characteristics and shorter duration of their disease. The association of glycemic control with MCM and PNM has been consistently documented (41) , so that should maternal glucose be the only important variable, better main outcomes should be expected in women with type 2 DM. Because this has not been the case, there should be other reasons accounting for worse PNM and similar SB and NM; prepregnancy BMI, age, and drug use could be potential ones.
Maternal overweight and obesity are associated with MCM (42) and fetal loss (miscarriage, SB, NM, and PNM) (43) (44) (45) (46) . When obesity and diabetes coexist, the risk of malformations is further increased (47) , with different contribution of obesity and hyperglycemia to different anomalies (48) . The role of BMI on PNM in women with type 2 DM has already been suggested by Cundy et al. (34) . Thus, BMI being a potent predictor of adverse pregnancy outcome, we hypothesized that the higher BMI in type 2 DM must have had a definite impact in the observed results. Nevertheless, in the meta-regression analyses, we were unable to identify BMI or any other variable as significant predictors. A weakness of these post hoc analyses is that they had low statistical power because only a small fraction of the original studies were included. Another source of adverse pregnancy outcome is maternal age. Advanced maternal age has been associated with a higher risk of PNM (49) and MCM (50) . Furthermore, in early pregnancy, women with type 2 DM are exposed not only to oral antidiabetic agents but also probably to other drugs such as antihypertensive and hypolipidemic agents, potentially contributing to a higher rate of MCM. Although the teratogenicity of oral antidiabetic agents is not clear (51) , some contribution could be expected for antihypertensive (52) and hypolipidemic drugs (53) .
Other factors difficult to measure, such as features associated with type 2 DM (social deprivation and ethnicity) or differences in the management protocol even in the same center, could also account for the poor pregnancy outcomes in these women. As to secondary outcomes, the lower risk of diabetic ketoacidosis in women with type 2 DM was not unexpected due to the intrinsically better ␤-cell function of type 2 DM at this stage. To interpret the reduced rate of cesarean section, we consider two possible explanations, both of them speculative: higher parity in women with type 2 DM making cesarean section unnecessary and/or obstetrician bias to perform more cesarean sections in women with type 1 DM.
Most of the studies included in this review analyze the influence of some predictor on some perinatal outcome. However, only a single paper attempts a multivariate analysis. Verheijen et al. (30) analyze the usefulness of five variables (age, ethnicity, type of DM, prepregnancy insulin therapy, and gestational age at booking) to predict a composite outcome (total pregnancy loss and/or congenital anomaly). The predictors in the adjusted model were ethnicity and insulin treatment before pregnancy, but it is important to note that prepregnancy BMI was not considered in the analysis.
In comparison with pregnant women with type 1 DM, at the time of pregnancy, those with type 2 DM have a lower duration of diabetes, lower figures of HbA1c, and lower rates of diabetic complications. However, according to the results of this study, both healthcare providers and administrators should be aware that in terms of pregnancy outcome, the seriousness of their condition is similar if not worse. The pathophysiology underlying the higher perinatal mortality in women with type 2 DM remains to be established. Well-designed multivariate analysis studying the contribution of different predictors on perinatal outcomes would be required.
In conclusion, despite a milder glycemic disturbance, women with type 2 DM had no better perinatal outcomes than those with type 1, indicating that type 2 DM in pregnancy is a serious condition.
